Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease.

ABSTRACT:

Objectives

Chronic obstructive pulmonary disease (COPD) is more prevalent in HIV-infected individuals and is associated with persistent inflammation. Therapies unique to HIV are lacking. We performed a pilot study of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin to determine effects on lung function.

Design

Randomized, placebo-controlled, triple-blinded trial.

Methods

HIV-infected individuals with abnormal lung function were recruited from an ongoing lung function study. Participants were randomized to 24 weeks of placebo (n = 11) or rosuvastatin (n = 11) using an adaptive randomization based on change in peripheral C-reactive protein levels at 30 days of treatment. Forced expiratory volume in 1 s (FEV1) and diffusing capacity for carbon m

SUBMITTER: Morris A 

PROVIDER: S-EPMC5263188 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature